OncoStem Diagnostics

CanAssist-Breast has been clinically validated to accurately assess the risk of distant recurrence in early-stage hormone receptor positive breast cancer patients. The test uses a combination of five protein biomarkers analyzed via IHC and an AI-powered algorithm to generate a personalized recurrence risk score within five years post-surgery. It helps clinicians tailor treatment plans—potentially sparing low-risk patients from unnecessary chemotherapy while ensuring high-risk patients receive aggressive therapy when needed. The product has been adopted across India and several international markets since its launch in 2016. Clinical results have demonstrated robust performance comparable to global standards.